肝胆胰恶性肿瘤腹腔化疗专家共识(2020版)

2020-12-09 肝胆外科专家组(统称) 中华肝脏外科手术学电子杂志.2020(6):522-528.

腹腔化疗是高选择性的区域化疗,主要用于治疗腹膜的原发和继发肿瘤及并发症。通过腹腔内应用化疗药物,能使高浓度药物直接与腹腔内肿瘤组织接触,并降低进入体循环的化疗药物浓度,减少毒副作用,同时与热疗协同增效

中文标题:

肝胆胰恶性肿瘤腹腔化疗专家共识(2020版)

发布日期:

2020-12-09

简要介绍:

腹腔化疗是高选择性的区域化疗,主要用于治疗腹膜的原发和继发肿瘤及并发症。通过腹腔内应用化疗药物,能使高浓度药物直接与腹腔内肿瘤组织接触,并降低进入体循环的化疗药物浓度,减少毒副作用,同时与热疗协同增效。腹腔化疗包括腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)、腹腔灌注化疗以及腹腔内药物(包括缓释剂)的局部使用,其中前者是指将含化疗药物的灌注液以恒定的温度循环灌注腹腔,使腹腔充盈并维持一定时间,是目前主要的腹腔化疗方式,临床应用最广。

相关资料下载:
[AttachmentFileName(sort=1, fileName=肝胆胰恶性肿瘤腹腔化疗专家共识_2020版_李川江.pdf)] GetToolGuiderByIdResponse(projectId=1, id=493721c00203a15c, title=肝胆胰恶性肿瘤腹腔化疗专家共识(2020版), enTitle=, guiderFrom=中华肝脏外科手术学电子杂志.2020(6):522-528., authorId=0, author=, summary=腹腔化疗是高选择性的区域化疗,主要用于治疗腹膜的原发和继发肿瘤及并发症。通过腹腔内应用化疗药物,能使高浓度药物直接与腹腔内肿瘤组织接触,并降低进入体循环的化疗药物浓度,减少毒副作用,同时与热疗协同增效, cover=https://img.medsci.cn/20201231/1609345035275_2020535.jpg, journalId=0, articlesId=null, associationId=701, associationName=肝胆外科专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed Dec 09 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>腹腔化疗是高选择性的区域化疗,主要用于治疗腹膜的原发和继发肿瘤及并发症。通过腹腔内应用化疗药物,能使高浓度药物直接与腹腔内肿瘤组织接触,并降低进入体循环的化疗药物浓度,减少毒副作用,同时与热疗协同增效。腹腔化疗包括腹腔热灌注化疗(hyperthermic intraperitoneal&nbsp;chemotherapy,HIPEC)、腹腔灌注化疗以及腹腔内药物(包括缓释剂)的局部使用,其中前者是指将含化疗药物的灌注液以恒定的温度循环灌注腹腔,使腹腔充盈并维持一定时间,是目前主要的腹腔化疗方式,临床应用最广。</p> </div> </div> </div>, tagList=[TagDto(tagId=81165, tagName=肝胆胰恶性肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=81165, guiderKeyword=肝胆胰恶性肿瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4846, appHits=238, showAppHits=0, pcHits=703, showPcHits=4608, likes=2, shares=12, comments=15, approvalStatus=1, publishedTime=Thu Dec 31 00:27:28 CST 2020, publishedTimeString=2020-12-09, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Dec 31 00:17:20 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 03:12:09 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=肝胆胰恶性肿瘤腹腔化疗专家共识_2020版_李川江.pdf)])
肝胆胰恶性肿瘤腹腔化疗专家共识_2020版_李川江.pdf
下载请点击:
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=996134, encodeId=a1da9961345e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0805237067, createdName=147b1f37m27暂无昵称, createdTime=Sun Jul 04 17:30:14 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996133, encodeId=b5f1996133d9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0805237067, createdName=147b1f37m27暂无昵称, createdTime=Sun Jul 04 17:29:57 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957110, encodeId=1aa695e11017, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c45480620, createdName=ms4000001215099885, createdTime=Wed Apr 14 22:53:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921434, encodeId=99b592143473, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=ms7000000982141651, createdTime=Sat Jan 30 20:28:59 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919934, encodeId=0726919934cf, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6145455679, createdName=ms6000001421147021, createdTime=Tue Jan 26 09:14:49 CST 2021, time=2021-01-26, status=1, ipAttribution=)]
    2021-07-04 147b1f37m27暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=996134, encodeId=a1da9961345e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0805237067, createdName=147b1f37m27暂无昵称, createdTime=Sun Jul 04 17:30:14 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996133, encodeId=b5f1996133d9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0805237067, createdName=147b1f37m27暂无昵称, createdTime=Sun Jul 04 17:29:57 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957110, encodeId=1aa695e11017, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c45480620, createdName=ms4000001215099885, createdTime=Wed Apr 14 22:53:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921434, encodeId=99b592143473, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=ms7000000982141651, createdTime=Sat Jan 30 20:28:59 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919934, encodeId=0726919934cf, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6145455679, createdName=ms6000001421147021, createdTime=Tue Jan 26 09:14:49 CST 2021, time=2021-01-26, status=1, ipAttribution=)]
    2021-07-04 147b1f37m27暂无昵称

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=996134, encodeId=a1da9961345e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0805237067, createdName=147b1f37m27暂无昵称, createdTime=Sun Jul 04 17:30:14 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996133, encodeId=b5f1996133d9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0805237067, createdName=147b1f37m27暂无昵称, createdTime=Sun Jul 04 17:29:57 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957110, encodeId=1aa695e11017, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c45480620, createdName=ms4000001215099885, createdTime=Wed Apr 14 22:53:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921434, encodeId=99b592143473, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=ms7000000982141651, createdTime=Sat Jan 30 20:28:59 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919934, encodeId=0726919934cf, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6145455679, createdName=ms6000001421147021, createdTime=Tue Jan 26 09:14:49 CST 2021, time=2021-01-26, status=1, ipAttribution=)]
    2021-04-14 ms4000001215099885

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=996134, encodeId=a1da9961345e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0805237067, createdName=147b1f37m27暂无昵称, createdTime=Sun Jul 04 17:30:14 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996133, encodeId=b5f1996133d9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0805237067, createdName=147b1f37m27暂无昵称, createdTime=Sun Jul 04 17:29:57 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957110, encodeId=1aa695e11017, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c45480620, createdName=ms4000001215099885, createdTime=Wed Apr 14 22:53:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921434, encodeId=99b592143473, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=ms7000000982141651, createdTime=Sat Jan 30 20:28:59 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919934, encodeId=0726919934cf, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6145455679, createdName=ms6000001421147021, createdTime=Tue Jan 26 09:14:49 CST 2021, time=2021-01-26, status=1, ipAttribution=)]
    2021-01-30 ms7000000982141651

    谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=996134, encodeId=a1da9961345e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0805237067, createdName=147b1f37m27暂无昵称, createdTime=Sun Jul 04 17:30:14 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996133, encodeId=b5f1996133d9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0805237067, createdName=147b1f37m27暂无昵称, createdTime=Sun Jul 04 17:29:57 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957110, encodeId=1aa695e11017, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73c45480620, createdName=ms4000001215099885, createdTime=Wed Apr 14 22:53:53 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921434, encodeId=99b592143473, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=ms7000000982141651, createdTime=Sat Jan 30 20:28:59 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919934, encodeId=0726919934cf, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6145455679, createdName=ms6000001421147021, createdTime=Tue Jan 26 09:14:49 CST 2021, time=2021-01-26, status=1, ipAttribution=)]
    2021-01-26 ms6000001421147021

    学习学习

    0